



# The Risk of Developing Ocular Involvement Among Behçet's Disease Patients Presenting with Mucocutaneous Involvement at Disease Onset: Data from the International AIDA Network Behçet's Disease Registry

Antonio Vitale · Valeria Caggiano · Jessica Sbalchiero · Giuseppe Lopalco · Gaafar Ragab ·  
Silvana Guerriero · Ibrahim AlMaglouth · Abdurrahman Tufan · Roberto Giacomelli · Haner Direskeneli ·  
Piero Ruscitti · Gülen Hatemi · Francesco Carubbi · Ezgi Deniz Batu · Seza Ozen · Jurgén Sota ·  
Henrique Ayres Mayrink Giardini · Micol Frassi · Petros P. Sfikakis · Federica Gatti · Claudia Ammoscato ·  
Amina Maher · Ayman Abdel-Monem Ahmed Mahmoud · Rosanna Dammacco · Hamit Kucuk ·  
Riza Can Kardas · Ibrahim Yahya Cakir · Fatma Alibaz Öner · Gizem Sevik · Martina Gentile · Alican Karakoc ·  
Alessia Alunno · Hulya Ercan Emreol · Francesca Crisafulli · Katerina Laskari · Francesco Ciccía ·  
Maissa Thabet · Naceur Feriel · Serena Bugatti · Alessandra Milanese · Maria Sole Chimenti · Benedetta Monosi ·  
Matteo Piga · Alberto Floris · Francesco Gavioli · Cecilia Beatrice Chighizola · José Hernández-Rodríguez ·  
Marco Cattalini · Marcello Govoni · Ombretta Viapiana · Adele Civino · Daniela Opris-Belinski ·  
Carla Gaggiano · Rosaria Talarico · Annachiara Alemanno · Annarita Giardina · Giacomo Emmi ·  
Piercarlo Sarzi Puttini · Maria Cristina Maggio · Paola Parronchi · Piero Portincasa · Alejandra de-la-Torre ·  
Laura Daniela Rodríguez-Camelo · Stefano Gentileschi · Angela Mauro · Gian Domenico Sebastiani ·  
Alma Nunzia Olivieri · Ali Şahin · Donato Rigante · Emre Bilgin · Emanuela Del Giudice · Luciana Breda ·  
Amato De Paulis · Alberto Lo Gullo · Şükran Erten · Samar Tharwat · Lampros Fotis · Armin Maier ·  
Antonella Insalaco · Anastasios Karamanakis · Alessandro Conforti · Özgül Soysal Gündüz ·  
Abdelhfeez Moshirif · Francesca Li Gobbi · Stefania Costi · Elena Bartoloni · Patrizia Barone · Serena Guiducci ·  
Andrés Gonzáles-García · Inés Hernanz Rodriguez · Giovanni Conti · Annamaria Iagnocco · Fatos Önen ·  
Sulaiman M. Al-Mayouf · Didar Uçar · Alberto Balistreri · Bruno Frediani · Luca Cantarini  · Claudia Fabiani

Received: August 22, 2025 / Accepted: September 29, 2025 / Published online: November 8, 2025  
© The Author(s) 2025

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1007/s40123-025-01258-0>.

A. Vitale · V. Caggiano · J. Sbalchiero · J. Sota ·  
F. Gavioli · C. Gaggiano · A. Alemanno · S. Gentileschi ·  
B. Frediani · L. Cantarini (✉)  
Rheumatology Unit, Department of Medical  
Sciences, Surgery and Neurosciences Department

of Medical Sciences, Surgery and Neurosciences,  
University of Siena and Azienda Ospedaliero-  
Universitaria Senese [European Reference  
Network (ERN) for Rare Immunodeficiency,  
Autoinflammatory, and Autoimmune Diseases  
(RITA) Center], Policlinico “Le Scotte”, Viale Bracci

16, 53100 Siena, Italy  
e-mail: cantariniluca@hotmail.com

A. Vitale  
e-mail: vitale.reumatologia@gmail.com

G. Lopalco · F. Gatti · C. Ammoscato  
Department of Precision and Regenerative Medicine  
and Ionian Area (DiMePre-J) Policlinic Hospital,  
University of Bari, Bari, Italy

G. Ragab · A. Maher · A. A.-M. A. Mahmoud  
Internal Medicine Department, Rheumatology  
and Clinical Immunology Unit, Faculty of Medicine,  
Cairo University, Giza, Egypt

G. Ragab · A. Maher · A. A.-M. A. Mahmoud  
Faculty of Medicine, Newgiza University, 6th of  
October City, Giza, Egypt

S. Guerriero · R. Dammacco  
Department of Translational Biomedicine  
and Neuroscience (DiBraiN), University of Bari, Bari,  
Italy

I. AlMaglouth  
Rheumatology Unit, Department of Medicine, King  
Saud University, Riyadh, Saudi Arabia

A. Tufan · H. Kucuk · R. Kardas · I. Y. Cakir  
Division of Rheumatology, Department of Internal  
Medicine, Gazi University Hospital, Ankara, Turkey

R. Giacomelli  
Rheumatology, Immunology and Clinical Medicine  
Unit, Department of Medicine, Università Campus  
Bio-Medico Di Roma, Rome, Italy

H. Direskeneli · F. A. Öner · G. Sevik  
Department of Internal Medicine, Division  
of Rheumatology, School of Medicine, Marmara  
University, Istanbul, Turkey

P. Ruscitti · M. Gentile  
Rheumatology Unit, Department  
of Biotechnological and Applied Clinical Sciences,  
University of L'Aquila, L'Aquila, Italy

G. Hatemi · A. Karakoc  
Department of Internal Medicine, Division  
of Rheumatology, Cerrahpasa Medical School,  
Istanbul University-Cerrahpasa, Istanbul, Turkey

F. Carubbi · A. Alunno  
Behçet's Disease Research Center, Istanbul  
University-Cerrahpasa, Istanbul, Turkey

F. Carubbi · E. D. Batu · A. Alunno  
Department of Life, Health & Environmental  
Sciences, Internal Medicine and Nephrology  
Division, ASL1 Avezzano-Sulmona-L'Aquila, San  
Salvatore Hospital, University of L'Aquila, L'Aquila,  
Italy

S. Ozen · H. E. Emreol  
Pediatric Rheumatology Unit, Department  
of Pediatrics, Hacettepe University School

of Medicine, Ankara, Turkey

H. A. M. Giardini  
Rheumatology Division, Faculdade de Medicina,  
Hospital das Clinicas (HCFMUSP), Universidade de  
Sao Paulo, Sao Paulo, Brazil

M. Frassi · F. Crisafulli  
Rheumatology and Clinical Immunology, Spedali  
Civili and Department of Clinical and Experimental  
Sciences, University of Brescia, [European Reference  
Network (ERN) for Rare Immunodeficiency,  
Autoinflammatory and Autoimmune Diseases  
(RITA) Center], Brescia, Italy

P. P. Sfrikakis · K. Laskari  
Joint Academic Rheumatology Program, National  
and Kapodistrian University of Athens Medical  
School, [European Reference Network (ERN)  
for Rare Immunodeficiency, Autoinflammatory  
and Autoimmune Diseases (RITA) Center], Athens,  
Greece

F. Ciccica  
Department of Precision Medicine, Università Degli  
Studi Della Campania Luigi Vanvitelli, Naples, Italy

M. Thabet · N. Feriel  
Internal Medicine Department, Farhat Hached  
University Hospital, Faculty of Medicine of Sousse,  
University of Sousse, Sousse, Tunisia

S. Bugatti · A. Milanese  
Department of Internal Medicine and Therapeutics,  
Università Di Pavia and Division of Rheumatology,  
Fondazione IRCCS Policlinico San Matteo, Pavia,  
Italy

M. S. Chimenti · B. Monosi  
Rheumatology, Allergology and Clinical  
Immunology, Department of Systems Medicine,  
University of Rome Tor Vergata, Rome, Italy

M. Piga  
Rheumatology Unit, Department of Medical  
Sciences, University and AOU of Cagliari, Cagliari,  
Italy

A. Floris · C. B. Chighizola  
Pediatric Rheumatology Unit, Azienda Socio-  
Sanitaria Territoriale (ASST) Gaetano Pini Centro  
Specialistico Ortopedico Traumatologico (CTO),  
Milan, Italy

C. B. Chighizola · S. Costi  
Department of Clinical Sciences and Community  
Health, Research Center for Adult and Pediatric  
Rheumatic Diseases, University of Milan, Milan,  
Italy

J. Hernández-Rodríguez  
Autoinflammatory Diseases Clinical Unit,  
Department of Autoimmune Diseases, Hospital  
Clinic of Barcelona, August Pi I Sunyer Biomedical  
Research Institute (IDIBAPS), University  
of Barcelona, Barcelona, Spain

- M. Cattalini  
Pediatric Clinic, University of Brescia and Spedali Civili Di Brescia [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory, and Autoimmune Diseases (RITA) Center], Brescia, Italy
- M. Govoni  
Rheumatology Unit, Department of Medical Sciences, Azienda Ospedaliero-Universitaria S. Anna - Ferrara, University of Ferrara, Ferrara, Italy
- O. Viapiana  
Rheumatology Unit, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy
- A. Civino  
Pediatric Rheumatology and Immunology Unit, Vito Fazzi Hospital, 73100 Lecce, Italy
- D. Opris-Belinski  
Rheumatology and Internal Medicine Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
- R. Talarico  
Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- A. Giardina  
UOC Medicina Interna, Ambulatorio Di Reumatologia, ARNAS Civico Di Cristina Benfratelli, Palermo, Italy
- G. Emmi  
Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy
- G. Emmi  
Clinical Medicine and Rheumatology Unit, Cattinara University Hospital, Trieste, Italy
- G. Emmi  
Centre for Inflammatory Diseases, Department of Medicine, Monash Medical Centre, Monash University, Clayton, VIC, Australia
- P. S. Puttini  
Rheumatology Unit, Ospedale Sacco, Milan, Italy
- M. C. Maggio  
University Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE) “G. D’Alessandro”, University of Palermo, Palermo, Italy
- P. Parronchi  
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
- P. Portincasa  
Clinica Medica “A. Murri”, Division of Internal Medicine, Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), University of Bari Aldo Moro, Bari, Italy
- A. de-la-Torre · L. D. Rodríguez-Camelo  
Neuroscience Research Group (NEUROS), Neurovitae Center for Neuroscience, Institute of Translational Medicine (IMT), School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia
- A. Mauro  
Department of Biomedical and Clinical Sciences, Fatebenefratelli Hospital, Università Di Milano, Milan, Italy
- A. Mauro  
Pediatric Rheumatology Unit, Department of Childhood and Developmental Medicine, Fatebenefratelli-Sacco Hospital, Milan, Italy
- G. D. Sebastiani  
U.O.C. Reumatologia, Ospedale San Camillo-Forlanini, Rome, Italy
- A. N. Olivieri  
Department of Woman, Child and of General and Specialized Surgery, University of Campania “Luigi Vanvitelli”, Naples, Italy
- A. Şahin  
Division of Rheumatology, Department of Internal Medicine, Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey
- D. Rigante  
Department of Life Sciences and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- D. Rigante  
Rare Diseases and Periodic Fevers Research Centre, Università Cattolica Sacro Cuore, Rome, Italy
- E. Bilgin  
Faculty of Medicine, Division of Rheumatology, Sakarya University, Sakarya, Turkey
- E. Del Giudice  
Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome, Polo Pontino, Rome, Italy
- L. Breda  
Department of Paediatrics, University of Chieti-Pescara, Chieti, Italy
- A. De Paulis  
Department of Translational Medical Sciences, Section of Clinical Immunology, University of Naples Federico II, Naples, Italy
- A. De Paulis  
Center for Basic and Clinical Immunology Research (CISI), WAO Center of Excellence, University of Naples Federico II, Naples, Italy
- A. L. Gullo  
Unit of Rheumatology, Department of Medicine, ARNAS Garibaldi Hospital, Catania, Italy

Ş. Erten

Department of Rheumatology, Faculty of Medicine  
Ankara City Hospital, Ankara Yildirim Beyazit  
Universitesi, Ankara, Turkey

S. Tharwat

Rheumatology and Immunology Unit, Internal  
Medicine Department, Mansoura University,  
Mansoura, Egypt

S. Tharwat

Department of Internal Medicine, Faculty  
of Medicine, Horus University, New Damietta, Egypt

L. Fotis

Department of Pediatrics, Attikon General Hospital,  
National and Kapodistrian University of Athens,  
Athens, Greece

A. Maier

Rheumatology Unit, Department of Medicine,  
Central Hospital of Bolzano, Bolzano, Italy

A. Insalaco

Division of Rheumatology, Ospedale Pediatrico  
Bambino Gesù, IRCCS [European Reference  
Network (ERN) for Rare Immunodeficiency,  
Autoinflammatory and Autoimmune Diseases  
(RITA) Center], Rome, Italy

A. Karamanakos

Department of Rheumatology, “Evangelismos”  
General Hospital, Athens, Greece

A. Conforti

Ospedale San Paolo Di Civitavecchia, U.O. Medicina  
Generale, ASL Roma 4, Civitavecchia, Rome, Italy

Ö. S. Gündüz

Division of Rheumatology, Department of Internal  
Medicine, School of Medicine, Manisa Celal Bayar  
University, Manisa, Turkey

A. Moshrif

Rheumatology Department, Faculty of Medicine,  
Al-Azhar University, Assiut, Egypt

F. L. Gobbi

Rheumatology Unit, Hospital S. Giovanni Di Dio,  
Azienda USL-Toscana Centro, Florence, Italy

E. Bartoloni

Rheumatology Unit, Department of Medicine  
and Surgery, University of Perugia, Perugia, Italy

P. Barone

Department of Clinical and Experimental Medicine,  
University of Catania, Catania, Italy

S. Guiducci

Division of Rheumatology, Department  
of Experimental and Clinical Medicine, University  
of Florence, Florence, Italy

A. Gonzáles-García

Systemic Autoimmune Diseases Unit, Department  
of Internal Medicine, Hospital Universitario Ramón  
y Cajal, IRYCIS, Madrid, Spain

I. H. Rodriguez

Department of Ophthalmology, Hospital  
Universitario Fundación Jiménez Díaz, Madrid,  
Spain

G. Conti

Pediatric Nephrology and Rheumatology Unit,  
Azienda Ospedaliero Universitaria (AOU) G Martino,  
Messina, Italy

A. Iagnocco

Academic Rheumatology Center, Dipartimento  
Scienze Cliniche e Biologiche, Università Degli Studi  
Di Torino, Turin, Italy

F. Önen

School of Medicine, Department of Internal  
Medicine, Division of Rheumatology, Dokuz Eylül  
University, Izmir, Turkey

S. M. Al-Mayouf

King Faisal Specialist Hospital and Research Center,  
College of Medicine, Department of Pediatrics,  
Alfaisal University, Riyadh, Saudi Arabia

D. Uçar

Department of Ophthalmology, Cerrahpasa Medical  
School, Istanbul University-Cerrahpasa, Istanbul,  
Turkey

A. Balistreri

Bioengineering and Biomedical Data Science Lab,  
Department of Medical Biotechnologies, University  
of Siena, [European Reference Network (ERN)  
for Rare Immunodeficiency, Autoinflammatory,  
and Autoimmune Diseases (RITA) Center], Siena,  
Italy

C. Fabiani

Ophthalmology Unit, Department of Medicine,  
Surgery and Neurosciences, University of Siena  
and Azienda Ospedaliero-Universitaria Senese  
[European Reference Network (ERN) for Rare  
Immunodeficiency, Autoinflammatory,  
and Autoimmune Diseases (RITA) Center], Siena,  
Italy

## ABSTRACT

**Introduction:** Behçet's disease (BD) frequently arises with exclusively mucocutaneous involvement, but some patients will develop major organ involvement, including ocular inflammation. This study aims to assess the patients' demographic and clinical characteristics that may be associated with the development of ocular involvement in patients with BD with exclusively mucocutaneous involvement in the early stages.

**Methods:** Patients' data were collected in the International AutoInflammatory Disease Alliance (AIDA) Network registry dedicated to BD.

**Results:** A total of 328 patients with BD were enrolled, 36 (11%) of whom developed ocular involvement over time. The following variables were significantly associated with the development of ocular inflammation at binary logistic regression: positive family history for BD (OR 4.32, 95% CI 1.16–14.72,  $p=0.02$ ), Arab ethnicity (OR 3.6, 95% CI 1.3–9.9,  $p=0.01$ ), presence of major oral aphthous ulceration (OR 3.26, 95% CI 1.18–8.99,  $p=0.02$ ), pseudofolliculitis plus erythema nodosum (OR 4.58, 95% CI 1.33–15.7,  $p=0.016$ ); conversely, white patients/patients of European descent (OR 0.33, 95% CI 0.12–0.91,  $p=0.03$ ) and the presence of a low number (one to two) ulcers at genital aphthous flares (OR 0.002, 95% CI ~0–0.07,  $p=0.0006$ ) were protective against the occurrence of ocular inflammatory manifestations. Genital aphthosis with more than five concurrent ulcers was associated with eye involvement in Arab patients (OR 209.2, 95% CI 5.8–7497,  $p=0.003$ ).

**Conclusions:** Major oral aphthosis, genital aphthous attacks with more than five concurrent ulcers, erythema nodosum coexisting with pseudofolliculitis, a positive family history of BD, and Arab ethnicity are associated with a higher risk of ocular involvement when BD arises with the sole mucocutaneous involvement.

**Keywords:** Uveitis; Retinal vasculitis; International registry; AIDA Network; Rare diseases

## INTRODUCTION

Mucocutaneous involvement is the hallmark of Behçet's disease (BD) and often represents the only clinical manifestation for an extended period in these patients. Specifically, mucocutaneous involvement includes the presence of oral aphthosis, which can be classified as minor or major depending on whether they are smaller or larger than 10 mm, genital ulcers, pseudofolliculitis, erythema nodosum, skin ulcers, pyoderma gangrenosum, and rarer skin manifestations [1, 2].

While some patients who initially present with exclusively mucocutaneous involvement will continue to experience only mucocutaneous manifestations, others will develop major organ involvement, including ocular, intestinal, central nervous system, and vascular BD-related affections [3, 4]. Ocular involvement, which is relatively common among patients with BD, can lead to a severe reduction in visual acuity or even complete blindness if not properly diagnosed and treated in a timely manner [5]. Therefore, identifying which patients are more likely to develop ocular involvement over time is of significant practical value and would provide helpful information for stratifying patients who initially present with exclusive mucocutaneous involvement but will later develop ocular inflammation. This study was conducted to assess the demographic and clinical characteristics of BD patients with exclusively mucocutaneous involvement at disease onset that may be associated with the development of ocular involvement in later stages.

## METHODS

Patients' data were collected in the International AutoInflammatory Disease Alliance (AIDA) Network registry dedicated to BD [6]. The Ethics Committee of Azienda Ospedaliero-Universitaria Senese, Siena, Italy (Ref. N. 14,951; NCT05200715) approved the study, which was performed according to the Good Clinical

Practice guidelines and the latest Declaration of Helsinki. Written informed consents for involved patients were collected at the time of patient enrollment in the AIDA registry and included permission to use data for research purposes. Clinical data are kept in accordance with the EU General Data Protection Regulations (GDPR), or other counterparts, on the processing of personal data and the protection of privacy (2016/679/EU). All patients included in the study fulfilled the International Study Group (ISG) criteria and/or the International Criteria for Behçet's Disease (ICBD) [7, 8].

This study aims to identify any demographic or clinical patients' features of patients with BD with exclusively mucocutaneous involvement in the early phase of the disease that may represent predictive factors of ocular involvement development in later stages. Therefore, patients presenting exclusively with oral aphthosis, genital aphthosis, and BD-related cutaneous manifestations, in the absence of ocular, intestinal, vascular, or central nervous system involvement for at least 12 months following disease onset, were included in the study. Disease onset was defined as when the patient fulfilled the classification criteria for BD, while ocular involvement was defined as the onset of uveitis, scleritis, or retinal vasculitis. Subsequently, patients who developed ocular involvement were identified and distinguished from those who remained free of ocular manifestations throughout the entire follow-up period. Follow-up was defined as the interval from disease onset (time at fulfillment of classification criteria) to the last available follow-up visit or the date of ocular involvement. Demographic, genetic, and clinical data were retrieved from the AIDA Registry dedicated to BD and subjected to statistical analysis [6].

Oral aphthae were classified as minor (< 10 mm in diameter) or major (> 10 mm), or herpetiform, the latter being characterized by numerous, small, and clustered oral lesions [1]. Patients were also stratified into three groups based on the number of concomitant oral ulcers observed during aphthous attacks: 1–2 ulcers, 3–5 ulcers, and more than five ulcers. A similar stratification was performed according to the number of concomitant genital ulcers during aphthous flares. Cutaneous involvement was

evaluated through the presence of pseudofolliculitis, erythema nodosum, and a range of less common skin manifestations, including pyoderma gangrenosum, suppurative panniculitis, cutaneous ulcers, maculopapular eruptions, bullous erythema, hidradenitis suppurativa, urticarial lesions, erythema induratum, and erythema multiforme, which were collectively termed as "other skin manifestations".

The various mucocutaneous manifestations and their combinations (when identified in at least ten patients) were analyzed to assess their potential association with the development of ocular involvement over the course of the disease. Specifically, a binary multiple logistic regression model was employed, in which each patient feature was individually tested as an independent variable, while the presence or absence of ocular involvement over time served as the dependent variable. The total duration of follow-up (in years) was included as an adjustment covariate in all logistic regression models to account for differences in observation time across patients. Similarly, all logistic regression models were adjusted for the use of conventional disease-modifying anti-rheumatic drugs and the use of tumor necrosis factor inhibitors, as these treatments might influence the clinical expression of BD and, consequently, the likelihood of developing ocular involvement. Binary multiple logistic regressions were implemented using a mixed-effects model with both random intercepts and random slopes for ethnicity. This modelling approach allowed for the estimation of (i) the baseline variability in ocular involvement risk attributable to ethnicity, also expressed as the intraclass correlation coefficient (ICC%) in percentage; (ii) the extent to which the effect of each independent variable on ocular involvement varied across ethnic groups; and (iii) the residual variance unexplained by the fixed and random effects.

Based on the estimated beta coefficients, the predicted probability of developing ocular involvement was calculated for each variable significantly associated with the outcome. To this end, the formula  $\exp(\beta_0 + \beta_1) / [1 + \exp(\beta_0 + \beta_1)]$  was applied. This probability was further stratified according to the two most represented ethnic groups in the cohort—Arab and white

**Table 1** Demographic and clinical features of patients enrolled

| Patients' features                                                     | Description     |
|------------------------------------------------------------------------|-----------------|
| Sex (F/M)                                                              | 182/146         |
| <i>Ethnicity<sup>#</sup></i>                                           |                 |
| White patients/patients of European descent, <i>n</i> (%)              | 209 (63.7)      |
| Arab, <i>n</i> (%)                                                     | 60 (18.3)       |
| Turkish origin, <i>n</i> (%)                                           | 43 (13.1)       |
| Hispanic, <i>n</i> (%)                                                 | 6 (1.8)         |
| Other ethnicities, <i>n</i> (%)                                        | 7 (2.1)         |
| Age at disease onset, years (mean $\pm$ SD)                            | 29.1 $\pm$ 14.7 |
| Age at disease diagnosis, years (mean $\pm$ SD)                        | 34.8 $\pm$ 13.9 |
| HLA-B51 positivity, <i>n</i> (%) <sup>*</sup>                          | 156 (47.6)      |
| Positive family history, <i>n</i> (%)                                  | 35 (10.7)       |
| Pregnancy during the disease, <i>n</i> (% on females)                  | 22 (12.1)       |
| <i>Type of ocular involvement over time</i>                            |                 |
| Age at the onset of ocular involvement, years (mean $\pm$ SD)          | 35.8 $\pm$ 13.6 |
| Monolateral/bilateral                                                  | 18/18           |
| Uveitis, <i>n</i> (%)                                                  | 30 (9.1)        |
| Retinal vasculitis, <i>n</i> (%)                                       | 6 (1.8)         |
| <i>Ocular inflammation by ethnicity</i>                                |                 |
| White patients/patients of European descent, <i>n</i> (% within group) | 22 (10.5)       |
| Arab, <i>n</i> (% within group)                                        | 11 (18.3)       |
| Turkish origin, <i>n</i> (% within group)                              | 2 (4.7)         |
| Hispanic, <i>n</i> (% within group)                                    | 0 (0)           |
| Other ethnicities, <i>n</i> (% within group)                           | 1 (14.3)        |

CNS central nervous system, *F* females, *HLA* human leukocyte antigen, *M* males, *n* number, *SD* standard deviation

<sup>#</sup> not provided in three cases; <sup>\*</sup>in 60 cases HLA-B evaluation not performed

patients/ patients of European descent—as well as individuals of Turkish origin. Actually, given the epidemiologic relevance of Behçet's disease in Turkey, the Turkish group was evaluated separately. The probability was calculated by incorporating the random effects terms ( $\mu_0$  and  $\mu_1$ ) into the formula:  $\exp(\beta_0 + \mu_0 + \beta_1 + \mu_1) / [1 + \exp(\beta_0 + \mu_0 + \beta_1 + \mu_1)]$ . The coefficients  $\beta_0$ ,  $\beta_1$  and the random effects  $\mu_0$ ,  $\mu_1$  were derived from

binary multiple logistic regression models fitted using a mixed-effects framework.

Binary multiple logistic regression analysis was supplemented by the calculation of odds ratios (ORs), obtained by exponentiating the beta coefficients associated with each independent variable of interest, along with their 95% confidence intervals (95% CI) and corresponding *p* values.

**Table 2** Associations between the specific patients' features and the development of ocular involvement among patients presenting with exclusively mucocutaneous involvement at the start of Behçet's disease

| Patients' features                                      | Odds ratio (95% CI) | <i>p</i> value |
|---------------------------------------------------------|---------------------|----------------|
| Sex (male)                                              | 1.15 (0.42–3.07)    | 0.77           |
| Sex (female)                                            | 0.87 (0.32–2.36)    | 0.77           |
| Age at disease onset, years                             | 0.99 (0.95–1.02)    | 0.65           |
| Early onset (< 16 years)                                | 1.69 (0.49–5.18)    | 0.37           |
| HLA-B51 (no- > yes)*                                    | 0.99 (0.28–3.53)    | 0.99           |
| Positive family history for BD (no- > yes)              | 4.32 (1.16–14.72)   | 0.02           |
| Pregnancy history after disease onset (no- > yes)#      | 0.52 (0.02–3.69)    | 0.57           |
| BMI                                                     | 1.04 (0.93–1.15)    | 0.43           |
| Smoking status                                          | 1.37 (0.40–4.05)    | 0.58           |
| Presence of comorbidities (no- > yes)                   | 1.99 (0.69–5.64)    | 0.19           |
| Rheumatologic comorbidities (no- > yes)                 | 2.09 (0.10–14.83)   | 0.52           |
| Endocrinologic comorbidities (no- > yes)                | 0.83 (0.04–5.15)    | 0.86           |
| Arterial hypertension (no- > yes)                       | 1.46 (0.30–5.36)    | 0.6            |
| Pneumological comorbidities (no- > yes)                 | 1.23 (0.06–7.71)    | 0.85           |
| Neurological comorbidities (no- > yes)                  | 2.92 (0.35–15.90)   | 0.24           |
| Malignant oncological comorbidities (no- > yes)         | 5.62 (0.26–46.04)   | 0.14           |
| <i>Ethnic groups##</i>                                  |                     |                |
| Arab (no- > yes)                                        | 3.6 (1.3–9.9)       | 0.01           |
| White patients/patients of European descent (no- > yes) | 0.33 (0.12–0.91)    | 0.03           |
| Turkish origin (no- > yes)                              | 0.56 (0.07–4.75)    | 0.61           |
| Arab vs white patients/patients of European descent     | 3.76 (1.31–10.81)   | 0.01           |
| Arab vs. Turkish                                        | 4.03 (0.45–36.1)    | 0.21           |
| <i>Oral aphthous features</i>                           |                     |                |
| Concurrent oral ulcers (1–2 lesions) <sup>§</sup>       | 0.6 (0.17–2.1)      | 0.42           |
| Concurrent oral ulcers (3–5) <sup>§</sup>               | 1.7 (0.56–5.2)      | 0.35           |
| Concurrent oral ulcers (> 5) <sup>§</sup>               | 0.85 (0.21–3.5)     | 0.83           |
| Concurrent oral ulcers (3–5 vs. 1–2 lesions)            | 1.72 (0.48–7.18)    | 0.42           |
| Concurrent oral ulcers (3–5 vs. 1–2 lesions)            | 1.04 (0.17–5.61)    | 0.95           |
| Minor oral aphthous ulcerations (< 10 mm) (no- > yes)   | 1.07 (0.40–2.80)    | 0.88           |
| Major oral aphthous ulcerations (> 10 mm) (no- > yes)   | 3.26 (1.18–8.99)    | 0.02           |
| Oral herpetiform ulcerations (no- > yes)                | 0.83 (0.03–7.74)    | 0.88           |



Table 2 continued

| Patients' features                                                    | Odds ratio (95% CI)                 | <i>p</i> value |
|-----------------------------------------------------------------------|-------------------------------------|----------------|
| <i>Genital aphthous features</i>                                      |                                     |                |
| Genital aphthosis (no- > yes)                                         | 0.6 (0.22–1.62)                     | 0.3            |
| Concurrent genital ulcers (1–2 lesions) <sup>§§</sup>                 | 0.002 ( $6.8 \times 10^{-5}$ -0.07) | 0.0006         |
| Concurrent genital ulcers (3–5 lesions vs. 1–2 lesions) <sup>§§</sup> | 13.35 (0.84–213)                    | 0.07           |
| Concurrent genital ulcers (> 5 lesions vs. 1–2 lesions) <sup>§§</sup> | 209.2 (5.8–7497)                    | 0.003          |
| Skin involvement (no- > yes)                                          | 1.00 (0.37–2.89)                    | 0.99           |
| Pseudofolliculitis (no- > yes)                                        | 1.29 (0.49–3.38)                    | 0.59           |
| Erythema nodosum (no- > yes)                                          | 2.05 (0.69–5.83)                    | 0.17           |
| Other skin manifestations (no- > yes)                                 | 1.98 (0.36–8.36)                    | 0.38           |

The odds ratio, 95% confidence intervals (95% CI), and *p* values were derived from a multiple logistic regression model, with the development of ocular manifestations as the dependent variable and patient characteristics as independent variables, adjusted for disease duration and treatments performed. *BMI* body mass index, *HLA* human leukocyte antigen

\*Information not provided in 60 (18.3%) cases; #Performed on the subgroup of female patients; ##Considered the ethnic groups with at least 6 included patients; § information provided in 222 (68%) cases; §§ information provided in 152 out of 220 cases with genital ulcers

Descriptive statistical analysis was also performed, including calculating the mean, median, standard deviation, interquartile range, frequency counts, and corresponding percentages. Differences in non-normally distributed continuous variables were assessed using the Mann–Whitney *U* test, while differences in categorical variables were evaluated using the chi-squared test. The significance level was set at 95% (*p* value < 0.05), with *p* values being two-tailed. Statistical analysis was conducted using RStudio software, version 4.3.0.

## RESULTS

A total of 328 patients with Behçet's disease (BD) and exclusively mucocutaneous involvement at the disease onset were enrolled; of these, 36 (11%) patients developed ocular involvement over time, as better defined in Table 1. The median follow-up duration was 9.65 (IQR 11.0; range 0.08–64.7) years among patients without ocular involvement and 12.2 (IQR 8.25; range 1.42–24.2) years among patients developing

ocular inflammation (*p*=0.26). Notably, 63.9% of the episodes of ocular involvement occurred within 5 years from the onset of the disease, while 36.1% developed it later (*p*=0.01). Table 2 provides the data from the binary logistic regression associating the development of ocular involvement with demographic and clinical characteristics of patients with BD. In particular, having a positive family history for BD (OR 4.32, 95% CI 1.16–14.72, *p*=0.02), belonging to Arab ethnicity (OR 3.6, 95% CI 1.3–9.9, *p*=0.01), and showing major oral aphthosis (OR 3.26, 95% CI 1.18–8.99, *p*=0.02) was associated to the development of ocular inflammation over time. Conversely, white patients/ patients of European descent (OR 0.33, 95% CI 0.12–0.91, *p*=0.03) were protected against the development of ocular inflammation.

By including a random intercept and a random slope for the variables significantly associated with the onset of ocular involvement, we obtained the baseline variance related to the ethnic groups in the onset of ocular involvement, as well as the variance in the effect of each specific variable on the onset of ocular involvement

**Table 3** Associations between different combinations of mucocutaneous involvement observed at the start of the disease and the development of ocular inflammation developed over time

| Combinations of mucocutaneous affections                                         | Odds ratio (95% CI) | <i>p</i> value |
|----------------------------------------------------------------------------------|---------------------|----------------|
| Minor oral aphthosis + genital aphthosis                                         | 0.96 (0.35–1.6),    | 0.93           |
| Minor oral aphthosis + pseudofolliculitis                                        | 1.54 (0.5–4.7),     | 0.45           |
| Minor oral aphthosis + erythema nodosum                                          | 2.96 (0.82–10.4),   | 0.1            |
| Minor oral aphthosis + infrequent skin manifestations                            | 0.89 (0.09–8.9),    | 0.92           |
| Major oral aphthosis + genital aphthosis                                         | 4.4 (1.36–14.2),    | 0.01           |
| Major oral aphthosis + pseudofolliculitis                                        | 2.27 (0.64–8.04),   | 0.2            |
| Major oral aphthosis + erythema nodosum                                          | 1.4 (0.27–7.42),    | 0.69           |
| Genital aphthosis + pseudofolliculitis                                           | 0.84 (0.3–2.4),     | 0.75           |
| Genital aphthosis + erythema nodosum                                             | 2.44 (0.76–7.8),    | 0.13           |
| Genital aphthosis + infrequent skin manifestations                               | 1.08 (0.2–5.8),     | 0.92           |
| Pseudofolliculitis + erythema nodosum                                            | 4.58 (1.33–15.7),   | 0.016          |
| Pseudofolliculitis + infrequent skin manifestations                              | 3.57 (0.58–22.1),   | 0.17           |
| Minor oral aphthosis + genital aphthosis + pseudofolliculitis                    | 1.12 (0.29–4.28),   | 0.86           |
| Minor oral aphthosis + genital aphthosis + erythema nodosum                      | 2.51 (0.6–10.3),    | 0.2            |
| Major oral aphthosis + genital aphthosis + pseudofolliculitis                    | 3.3 (0.78–14.2),    | 0.1            |
| Genital aphthosis + pseudofolliculitis + erythema nodosum                        | 4.4 (1.17–16.55),   | 0.03           |
| Minor oral aphthosis + genital aphthosis + pseudofolliculitis + erythema nodosum | 3.6 (0.6–20.2),     | 0.15           |

The odds ratio, the corresponding 95% confidence interval (95% CI) and the *p* value were obtained through the binary logistic regression with ocular involvement being the dependent variable and the combinations of mucocutaneous involvement representing the independent variable. All regressions were adjusted for the duration of the total follow-up and the use of conventional or anti-tumor necrosis factor disease modifying anti-rheumatic drugs. Logistic regressions were conducted only when the combination of mucocutaneous affections involved at least ten patients at baseline

across different ethnicities. These data are provided in Supplementary Table 1.

Table 3 provides information on the associations between ocular development over time and the different combinations of ocular involvement observed at the onset of BD, while Table 4 provides the expected probabilities of developing ocular involvement if the patient is affected by the demographic or clinical manifestations that, according to the binary logistic regression analysis, were significantly associated with the development of ocular inflammation over time. More specifically, showing major oral aphthosis plus genital aphthosis (OR 4.4, 95% CI

1.36–14.2, *p*=0.01), pseudofolliculitis plus erythema nodosum (OR 4.58, 95% CI 1.33–15.7, *p*=0.016), and genital aphthosis plus pseudofolliculitis plus erythema nodosum (OR 4.4, 95% CI 1.17–16.55, *p*=0.03) was associated to the development of ocular inflammation over time.

## DISCUSSION

Ocular involvement is a common and clinically challenging BD complication, affecting 60–80% of patients and potentially leading to vision loss

**Table 4** Probability of developing ocular involvement in the whole cohort of patients and according to different ethnicities, based on the presence of variables significantly associated with ocular inflammation over time

| Variables associated with ocular involvement                 | Overall | Arab ethnicity<br>( <i>n</i> = 60) | White patients/patients<br>of European descent<br>( <i>n</i> = 209) | Turkish origin<br>( <i>n</i> = 43) |
|--------------------------------------------------------------|---------|------------------------------------|---------------------------------------------------------------------|------------------------------------|
| Overall probability to develop ocular inflammation           | 11%*    | 13.4%                              | 4.3%                                                                | 3.7%                               |
| Negative family history                                      | 4.6%    | 9.1%                               | 3.6%                                                                | 3.5%                               |
| Positive family history                                      | 20.6%   | 30.4%                              | 17.7%                                                               | 17.7%                              |
| Presence of major oral aphthosis                             | 22.5%   | 19.1%                              | 31.8%                                                               | 36%                                |
| One to two concomitant genital ulcers                        | 0.01%   | 2.4%                               | 0.006%                                                              | 0.001%                             |
| Three to five concomitant genital ulcers                     | 6.1%    | 5%                                 | 6.2%                                                                | 6.1%                               |
| More than five concomitant genital ulcers                    | ~ 0%    | 100%                               | ~ 0%                                                                | ~ 0%                               |
| Major oral aphthosis + genital aphthosis                     | 16.1%   | 53.9%                              | 11.1%                                                               | 7.4%                               |
| Pseudofolliculitis + erythema nodosum                        | 18.8%   | 37.1%                              | 14%                                                                 | 15.6%                              |
| Genital aphthosis + pseudofolliculitis + erythema<br>nodosum | 17%     | 37.5%                              | 11.7%                                                               | 13.2%                              |

Probabilities were estimated from the  $\beta$  coefficients and random effects for Arab and white patients/patients of European descent, derived from the multiple logistic regression models. Both the overall probability calculated from the entire cohort and the probabilities stratified by ethnic group are reported. Subgroup analysis by ethnicity was conducted only for the two most represented groups, namely Arab and white patients/patients of European descent

\*The probability was estimated as the ratio between the number of patients who developed ocular involvement over time and those who initially presented with exclusively mucocutaneous manifestations at the onset of Behçet's disease ( $36/328 = 0.1098$ )

if not adequately managed [5, 9, 10]. Identifying which patients are more likely to develop ocular inflammation is therefore of great clinical importance, especially in those who initially present with only mucocutaneous manifestations, as a substantial proportion of these patients later progress to major organ involvement [3, 4]. Among the variables examined, patient ethnicity emerged as a key determinant. Indeed, Arab ethnicity conferred a significantly increased risk of ocular involvement compared with both white patients/patients of European descent and Turkish patients, with estimated probabilities of 13.4%, 4.3%, and 3.7%, respectively.

With regard to mucocutaneous features, we confirmed previous observations [11] that genital aphthosis was associated with a lower probability of ocular involvement. However, our data suggest that this protective effect may be modulated by the number of concomitant

ulcers and by ethnicity. In particular, the presence of more than five genital ulcers was associated with ocular involvement in Arab patients, but not in white patients/patients of European descent or Turkish patients. This finding, although based on a small subgroup, highlights the potential interplay between clinical phenotype and ethnicity in shaping the risk of ocular disease, as also supported by Supplementary Table 1.

Notably, although the mere presence of genital ulcers demonstrated a non-significant but potentially protective odds ratio (as detailed in Table 2), specific mucocutaneous combinations appeared to reverse this protective trend. In particular, the co-occurrence of genital aphthosis with either major oral aphthosis or with the combination of pseudofolliculitis and erythema nodosum was associated with an increased likelihood of developing ocular inflammation. On

one hand, this effect appears to be driven by the presence of major aphthous ulcers, which are significantly associated with ocular involvement, with an increased likelihood of up to tenfold among patients of Turkish origin and more than sevenfold among white patients/patients of European descent. On the other hand, pseudofolliculitis and erythema nodosum, when considered separately, were not significantly associated with the development of ocular affections. However, their combination was strongly and significantly associated with ocular involvement, nullifying any protective effect of genital aphthosis, especially among Arab patients, but also among white patients/patients of European descent and Turkish patients. As illustrated in Table 4, the addition of genital aphthosis to the combination of pseudofolliculitis and erythema nodosum had a negligible impact on the probability of ocular involvement among patients of Arab ethnicity, increasing it only marginally from 37.1% to 37.5%. In contrast, a reduction of approximately one-sixth was observed among white patients/patients of European descent (from 14.0% to 11.7%) and among those of Turkish origin (from 15.6% to 13.2%). Although these latter probabilities may appear modest, they remain approximately 2.7–3.5 times higher than the baseline overall probability of ocular involvement in such populations.

Contrary to previous reports [3, 11], sex was not associated with ocular manifestations in the present cohort. This discrepancy may be attributable to the differing ethnic composition of the study populations—specifically, the absence of Japanese patients in the present cohort—as well as the inclusion criteria, which restricted this study to individuals with exclusive mucocutaneous involvement at BD onset. More notably, a positive family history of Behçet's disease emerged as a strong predictor of ocular involvement, conferring a nearly two- to fourfold increased risk across different populations. The impact of familial history on the risk of ocular inflammation was consistent across ethnic groups, as evidenced by the data provided in Supplementary Table 1. More in details, the variability in the impact of family history on the development of ocular involvement across different ethnicities was minimal, while greater

baseline differences in ocular involvement were observed between ethnic groups. However, the majority of the variance in the development of ocular involvement seemed to be driven by factors independent of both ethnic origin and family history.

Ghaleb RM et al. had already reported that the presence of skin lesions increased the risk of ocular involvement by 47-fold in patients with BD [12]. Overall, the findings presented in this study confirm an association between mucocutaneous manifestations and ocular inflammation, while offering more granular insight into the specific mucocutaneous features and their combinations that should alert clinicians to the possibility of future ocular involvement. Nevertheless, certain limitations must be acknowledged. Firstly, although the overall sample size is not particularly small, stratification into multiple subgroups based on the presence or absence of specific clinical manifestations limited the effective size of each subgroup. In some cases, this limit turned out to a high statistical uncertainty, highlighted by a very wide 95% CI. However, although the subdivision into subgroups inevitably reduced the sample size, the use of a mixed-effects model provided more robust estimates than a purely descriptive approach. The results, while to be interpreted with caution, still offer valuable insights into the clinical associations with ocular involvement in BD. In this context, the wide 95% CI and the limited number of statistically significant combinations highlight the exploratory nature of these findings, which should therefore be interpreted as hypothesis-generating. In particular, the association observed between genital aphthosis with more than five concurrent ulcers and ocular involvement among Arab patients was based on a very limited number of cases, which resulted in an extremely wide confidence interval (95% CI 5.8–7497). This highlights the statistical instability of this finding and underscores the need for cautious interpretation. While this result may suggest a possible trend, its confirmation in larger, prospective cohorts will be essential to validate and strengthen the associations suggested by our analysis.

Additionally, potential inclusion bias in the AIDA registry may have influenced the results.

Of note, 11 out of 60 Arabs, 22 out of 209 white patients/patients of European descent, and two out of 43 Turkish patients developed uveitis. While the number of Turkish patients with uveitis is admittedly small, this finding may be the direct expression of the lower tendency of this subgroup to develop ocular involvement when presenting with mucocutaneous-only disease, as highlighted by our analysis. However, the lower probability of developing ocular involvement among patients of Turkish origin could be partly explained by the tendency of Turkish centers to primarily enroll patients with more severe organ involvement from the onset of BD, while potentially underrepresenting cases with exclusive mucocutaneous manifestations. Lastly, the potential positivity of the pathergy test was not included in the statistical analysis, as this test is performed with considerable variability across different countries and clinical centers, which significantly affects its sensitivity and specificity [13–15].

## CONCLUSIONS

In conclusion, patients presenting with major oral aphthosis, those exhibiting both erythema nodosum and pseudofolliculitis, with or without genital ulcers, and individuals with a positive family history of BD are at significantly higher risk of developing ocular inflammatory involvement when the disease initially presents with mucocutaneous manifestations only. Patients of Arab ethnicity are at higher risk of developing BD-related ocular involvement; genital aphthosis, which is generally a protective factor, may not confer such protection among Arab patients when aphthous episodes occur with more than five ulcers.

## ACKNOWLEDGEMENTS

This research is supported (not financially) by the European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA). Some of the authors of this publication belong to institutes that are members of the ERN RITA [Antonio

Vitale, Valeria Caggiano, Jessica Sbalchiero, Jurgen Sota, Stefano Gentileschi, Alberto Balistreri, Bruno Frediani, Claudia Fabiani and Luca Cantarini [Azienda Ospedaliero-Universitaria Senese of Siena]; José Hernández-Rodríguez [Hospital Clínic of Barcelona]; Micol Frassi and Francesca Crisafulli [Spedali Civili, Brescia].

**Author Contributions.** All the authors substantially contributed to the conception or design of the work, the acquisition and interpretation of data, and critically revised the paper. All the authors approved the final version and agreed to be responsible for all aspects of the work. In addition, Antonio Vitale wrote the first draft of the manuscript and performed the preliminary data analysis and interpretation. Valeria Caggiano, Jessica Sbalchiero, Giuseppe Lopalco, Gaafar Ragab, Silvana Guerriero, Ibrahim AlMaglouth, Abdurrahman Tufan, Roberto Giacomelli, Haner Direskeneli, Piero Ruscitti, Gülen Hatemi, Francesco Carubbi, Ezgi Deniz Batu, Seza Ozen, Jurgen Sota, Henrique Ayres Mayrink Giardini, Micol Frassi, Petros P Sfikakis, Federica Gatti, Claudia Ammoscato, Amina Maher, Ayman Abdel-Monem Ahmed Mahmoud, Rosanna Dammaco, Hamit Kucuk, Riza Can Kardas, Ibrahim Yahya Cakir, Fatma Alibaz Öner, Gizem Sevik, Martina Gentile, Alican Karakoc, Alessia Alunno, Hulya Ercan Emreol, Francesca Crisafulli, Katerina Laskari, Francesco Ciccio, Maissa Thabet, Naceur Ferial, Serena Bugatti, Alessandra Milanese, Maria Sole Chimenti, Bendetta Monosi, Matteo Piga, Alberto Floris, Francesco Gavioli, Cecilia Beatrice Chighizola, José Hernández-Rodríguez, Marco Cattalini, Marcello Govoni, Ombretta Viapiana, Adele Civino, Daniela Opris-Belinski, Carla Gaggiano, Rosaria Talarico, Annachiara Alemanno, Annarita Giardina, Giacomo Emmi, Piercarlo Sarzi Puttini, Maria Cristina Maggio, Paola Parronchi, Piero Portincasa, Alejandra De-la-Torre, Laura Daniela Rodríguez-Camelo, Stefano Gentileschi, Angela Mauro, Gian Domenico Sebastiani, Alma Nunzia Olivieri, Ali Şahin, Donato Rigante, Emre Bilgin, Emanuela Del Giudice, Luciana Breda, Amato De Paulis, Alberto Lo Gullo, Şükran Erten, Samar Tharwat, Lampros Fotis, Armin Maier, Antonella Insalaco,

Anastasios Karamanakos, Alessandro Conforti, Özgül Soysal Gündüz, Abdelhfeez Moshirif, Francesca Li Gobbi, Stefania Costi, Elena Bartoloni, Patrizia Barone, Serena Guiducci, Andrés Gonzáles-Garcia, Inés Hernanz Rodríguez, Giovanni Conti, Annamaria Iagnocco, Fatos Önen, Sulaiman M. Al-Mayouf, Didar Uçar, Alberto Balistreri, Bruno Frediani, Luca Cantarini, Claudia Fabiani were involved in the study according to their active role in enrolling patients in the AIDA Network Registries; Alberto Balistreri, is also the bioengineer involved in the technical management of the platform and registries; Luca Cantarini took care of the final revision of the manuscript and accounted for AIDA Registries Coordinator. All authors meet the ICMJE criteria for authorship and are listed accordingly.

**Funding.** The authors declare that no financial support was received for the research and authorship of this article. No funding or sponsorship was received for the publication of this article.

**Data Availability.** The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation. Requests to access these datasets should be directed to the corresponding author: Luca Cantarini, MD, PhD, Research Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinics, Department of Medical Sciences, Surgery and Neurosciences, University of Siena. [cantariniluca@hotmail.com](mailto:cantariniluca@hotmail.com).

## Declarations

**Conflict of Interest.** The authors, therefore Antonio Vitale, Valeria Caggiano, Jessica Sbalchiero, Giuseppe Lopalco, Gaafar Ragab, Silvana Guerriero, Ibrahim AlMaglouth, Abdurrahman Tufan, Roberto Giacomelli, Haner Direskeneli, Piero Ruscitti, Gülen Hatemi, Francesco Carubbi, Ezgi Deniz Batu, Seza Ozen, Jurgen Sota, Henrique Ayres Mayrink Giardini, Micol Frassi, Petros P Sfikakis, Federica Gatti, Claudia Ammoscato, Amina Maher, Ayman Abdel-Monem Ahmed Mahmoud, Rosanna Dammaco, Hamit Kucuk, Riza Can Kardas, Ibrahim Yahya Cakir, Fatma Alibaz Öner,

Gizem Sevik, Martina Gentile, Alican Karakoc, Alessia Alunno, Hulya Ercan Emreol, Francesca Crisafulli, Katerina Laskari, Francesco Ciccia, Maissa Thabet, Naceur Feriel, Serena Bugatti, Alessandra Milanesi, Maria Sole Chimenti, Bendetta Monosi, Matteo Piga, Alberto Floris, Francesco Gavioli, Cecilia Beatrice Chighizola, José Hernández-Rodríguez, Marco Cattalini, Marcello Govoni, Ombretta Viapiana, Adele Civino, Daniela Opris-Belinski, Carla Gaggiano, Rosaria Talarico, Annachiara Alemanno, Annarita Giardina, Giacomo Emmi, Piercarlo Sarzi Puttini, Maria Cristina Maggio, Paola Parronchi, Piero Portincasa, Alejandra De-la-Torre, Laura Daniela Rodríguez-Camelo, Stefano Gentileschi, Angela Mauro, Gian Domenico Sebastiani, Alma Nunzia Olivieri, Ali Şahin, Donato Rigante, Emre Bilgin, Emanuela Del Giudice, Luciana Breda, Amato De Paulis, Alberto Lo Gullo, Şükran Erten, Samar Tharwat, Lampros Fotis, Armin Maier, Antonella Insalaco, Anastasios Karamanakos, Alessandro Conforti, Özgül Soysal Gündüz, Abdelhfeez Moshirif, Francesca Li Gobbi, Stefania Costi, Elena Bartoloni, Patrizia Barone, Serena Guiducci, Andrés Gonzáles-Garcia, Inés Hernanz Rodríguez, Giovanni Conti, Annamaria Iagnocco, Fatos Önen, Sulaiman M. Al-Mayouf, Didar Uçar, Alberto Balistreri, Bruno Frediani, Luca Cantarini, declare that the research was conducted without any commercial or financial relationships that could potentially create conflict of interest. Claudia Fabiani is an Editorial Board member of Ophthalmology and Therapy. She was not involved in the selection of peer reviewers for the manuscript nor any editorial decisions.

**Ethical Approval.** The Ethics Committee of Azienda Ospedaliero-Universitaria Senese, Siena, Italy (Ref. N. 14,951; NCT05200715) approved the study, which was performed according to the Good Clinical Practice guidelines and the latest Declaration of Helsinki. Written informed consents for involved patients were collected at the time of patient enrollment in the AIDA registry and included permission to use data for research purposes. Clinical data are kept in accordance with the EU General Data Protection Regulations (GDPR), or other counterparts, on the processing of personal data and the protection of privacy (2016/679/EU).



**Open Access.** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

## REFERENCES

- Nakamura K, Tsunemi Y, Kaneko F, Alpsoy E. Mucocutaneous manifestations of Behçet's disease. *Front Med*. 2021;7:613432. <https://doi.org/10.3389/fmed.2020.613432>.
- Alpsoy E, Bozca BC, Bilgic A. Behçet disease: an update for dermatologists. *Am J Clin Dermatol*. 2021;22(4):477–502. <https://doi.org/10.1007/s40257-021-00609-4>.
- Gürler A, Boyvat A, Türsen U. Clinical manifestations of Behçet's disease: an analysis of 2147 patients. *Yonsei Med J*. 1997;38(6):423–7. <https://doi.org/10.3349/ymj.1997.38.6.423>.
- Sota J, Rigante D, Emmi G, Lopalco G, Orlando I, Tosi GM, et al. Behçet's syndrome in Italy: a detailed retrospective analysis of 396 cases seen in 3 tertiary referral clinics. *Intern Emerg Med*. 2020;15(6):1031–9. <https://doi.org/10.1007/s11739-019-02248-4>.
- Lin S, Xu Z, Lin Z, Xie B, Feng J. Advances in pathogenesis and treatment of ocular involvement in Behçet's disease. *Front Immunol*. 2023;14:1206959. <https://doi.org/10.3389/fimmu.2023.1206959>.
- Vitale A, Della Casa F, Ragab G, Almaghlouth IA, Lopalco G, Pereira RM, et al. Development and implementation of the AIDA International Registry for patients with Behçet's disease. *Intern Emerg Med*. 2022;17(7):1977–86. <https://doi.org/10.1007/s11739-022-03038-1>.
- International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. *Lancet*. 1990;335(8697):1078–80.
- International Team for the Revision of the International Criteria for Behçet's Disease (ITR-ICBD). The international criteria for Behçet's disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. *J Eur Acad Dermatol Venereol*. 2014;28(3):338–47. <https://doi.org/10.1111/jdv.12107>.
- Deuter CM, Kötter I, Wallace GR, Murray PI, Stübiger N, Zierhut M. Behçet's disease: ocular effects and treatment. *Prog Retin Eye Res*. 2008;27(1):111–36. <https://doi.org/10.1016/j.preteyeres.2007.09.002>.
- Ozyazgan Y, Ucar D, Hatemi G, Yazici Y. Ocular involvement of Behçet's syndrome: a comprehensive review. *Clin Rev Allergy Immunol*. 2015;49(3):298–306. <https://doi.org/10.1007/s12016-014-8425-z>.
- Suwa A, Horita N, Ishido T, Takeuchi M, Kawagoe T, Shibuya E, et al. The ocular involvement did not accompany with the genital ulcer or the gastrointestinal symptoms at the early stage of Behçet's disease. *Mod Rheumatol*. 2019;29(2):357–62. <https://doi.org/10.1080/14397595.2018.1457424>.
- Ghaleb RM, Gad HS, Abdallah MI, Zaki ZM, Mahmoud JA. A proliferation-inducing ligand (APRIL) level among risk factors of ocular involvement in patients with Behçet's disease. *Reumatologia*. 2024;62(5):314–21. <https://doi.org/10.5114/reum/194113>.
- Shenavandeh S, Sadeghi SMK, Aflaki E. Pathergy test with a 23G needle with and without self-saliva in patients with Behçet's disease, recurrent aphthous stomatitis and control group compared to the 20G test. *Reumatologia*. 2021;59(5):302–8. <https://doi.org/10.5114/reum.2021.110567>.
- Kalay Yildizhan İ, Boyvat A. Diagnostic sensitivity of different applications of pathergy test for Behçet's disease. *Arch Rheumatol*. 2019;35(1):29–34. <https://doi.org/10.5606/ArchRheumatol.2020.7380>.
- Vitale A, Berlengiero V, Caggiano V, Barneschi S, Mourabi M, Sota J, et al. The diagnostic role of pathergy test in patients with Behçet's disease from Western Europe. *Intern Emerg Med*. 2023;18(1):77–83. <https://doi.org/10.1007/s11739-022-03117-3>.